γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
Science Advances · 05.05.2023 · 9 (18)
DOI: 10.1126/sciadv.adf0108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 05.05.2023. Verfasst von Jeremy S Frieling und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 77-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate-resistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using γδ-enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine model of bone mCRPC, γδ CAR-T cells targeting prostate stem cell antigen (PSCA) induced a rapid and significant regression of established tumors, combined with increased survival and reduced cancer-associated bone disease. Pretreatment with ZOL, a U.S. Food and Drug Administration–approved bisphosphonate prescribed to mitigate pathological fracture in mCRPC patients, resulted in CAR-independent activation of γδ CAR-T cells, increased cytokine secretion, and enhanced antitumor efficacy. These data show that the activity of the endogenous Vγ9Vδ2 T cell receptor is preserved in CAR-T cells, allowing for dual-receptor recognition of tumor cells. Collectively, our findings support the use of γδ CAR-T cell therapy for mCRPC treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Tumor Biology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
- Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
- Department of Pathology Research, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
ORCID-Profile: Jeremy S Frieling, Leticia Tordesillas, Ryan T Bishop, Junior E Cianne, Sebastian A Snedal, Tao Li, Chen Hao Lo, Janis de la Iglesia, Emiliano Roselli, Ismahène Benzaïd, Xuefeng Wang, Youngchul Kim, Conor C Lynch, Daniel Abate-Daga
Förderung
- NCI NIH HHS
Zitieren
APA
Frieling, J. S., Tordesillas, L., Bustos, X. E., Ramello, M. C., Bishop, R. T., Cianne, J. E., Snedal, S. A., Li, T., Lo, C. H., de la Iglesia, J., Roselli, E., Benzaïd, I., Wang, X., Kim, Y., Lynch, C. C., & Abate-Daga, D. (2023). γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Science Advances, 9(18). https://doi.org/10.1126/sciadv.adf0108
Vancouver
Frieling JS, Tordesillas L, Bustos XE, Ramello MC, Bishop RT, Cianne JE, et al. γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer. Science Advances. 2023;9(18). doi:10.1126/sciadv.adf0108
BibTeX
@article{Frieling2023,
author = {Frieling, Jeremy S and Tordesillas, Leticia and Bustos, Xiomar E and Ramello, Maria Cecilia and Bishop, Ryan T and Cianne, Junior E and Snedal, Sebastian A and Li, Tao and Lo, Chen Hao and de la Iglesia, Janis and Roselli, Emiliano and Benzaïd, Ismahène and Wang, Xuefeng and Kim, Youngchul and Lynch, Conor C and Abate-Daga, Daniel},
title = {γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {18},
doi = {10.1126/sciadv.adf0108}
}
EUVIMED